According to WiseGuy Reports, the Indocyanine Green API Market was valued at USD 247.8 million in 2024 and reached USD 264.1 million in 2025. The market is projected to reach USD 500 million by 2035, expanding at a CAGR of 6.6% during the forecast period from 2026 to 2035. Increasing diagnostic applications, the growing prevalence of liver diseases, advances in medical imaging, rising demand for minimally invasive procedures, and expanding pharmaceutical manufacturing capabilities are supporting market development. Key companies profiled include Huaian Hualu Pharmaceutical, Aldaghton, Fujifilm Holdings, Trivitron Healthcare, Akorn, Lantheus Medical Imaging, Boehringer Ingelheim, Sigma Aldrich, GE Healthcare, Taj Pharma, Sonafi, and Lianchuan Pharmaceutical.

Market Overview

Indocyanine green active pharmaceutical ingredient is used in medical imaging and diagnostic procedures where visualization of blood flow, tissue function, and anatomical structures is required. Its applications extend across cardiovascular imaging, oncology diagnosis, hepatic function assessment, and ocular imaging.

The market covers several formulation categories, including injection solutions, lyophilized powder, and liquid formulations. Hospitals, diagnostic laboratories, and research institutions represent key end-use environments, while direct sales, pharmacies, and online retail form the principal distribution channels.

Growing interest in image-guided procedures is creating a favorable environment for indocyanine green-based applications. Healthcare providers increasingly seek diagnostic approaches that can provide useful clinical information while supporting minimally invasive techniques.

Market Size Reached in 2025

The market reached USD 264.1 million in 2025, compared with USD 247.8 million in 2024. This increase reflects growing utilization of specialized diagnostic agents and continued investment in medical imaging capabilities.

Liver-related applications are particularly relevant because indocyanine green can assist in assessing hepatic function. Increasing attention to liver health and the diagnosis of related conditions can therefore contribute to demand.

Hospitals remain important consumers because imaging-supported diagnosis and surgical procedures are concentrated within clinical settings. Diagnostic laboratories and research institutions provide additional demand across testing and investigation activities.

Expected Market Size by 2035

The market is forecast to reach USD 500 million by 2035. Expansion is expected to be supported by broader diagnostic use and continuing improvements in imaging technologies.

Cardiovascular imaging represents an important application segment, while oncology diagnosis provides another area where improved visualization can support clinical decision-making. Ocular imaging and hepatic function assessment further diversify the market's application base.

Research institutions may also contribute to future growth as investigators explore additional uses for indocyanine green in medical imaging and pharmaceutical research.

Market CAGR

The market is expected to register a CAGR of 6.6% from 2026 through 2035. This growth rate reflects increasing clinical adoption, technological advancement, and expanding application opportunities.

The development of more sophisticated imaging systems can improve the practical utility of contrast agents and fluorescent compounds. As healthcare facilities upgrade diagnostic infrastructure, demand for compatible imaging products can increase.

Key Growth Drivers

The increasing use of diagnostic imaging is a primary market driver. Healthcare providers are adopting advanced visualization techniques to support diagnosis, monitoring, and procedural planning.

The prevalence of liver diseases also supports market demand. Hepatic function assessment is an established application area, giving the market exposure to a significant clinical need.

Minimally invasive surgery is another important factor. Surgeons increasingly use image-guided techniques to improve visualization during complex procedures, supporting demand for agents that can assist intraoperative imaging.

Pharmaceutical manufacturing expansion can additionally strengthen supply capabilities and improve the availability of formulations for clinical and research applications.

Emerging Market Trends

Medical imaging technology is progressing toward greater precision and real-time visualization. These developments can create new opportunities for fluorescent imaging agents and related pharmaceutical ingredients.

Research into oncology imaging is another emerging trend. The ability to visualize tissues and vascular structures can support research into more targeted diagnostic and surgical approaches.

Formulation development is also becoming relevant as manufacturers seek stable, convenient, and reliable dosage forms. Improvements in pharmaceutical processing can support product quality and distribution.

The expansion of research applications may further broaden the role of indocyanine green beyond established diagnostic procedures.

Competitive Landscape

The competitive landscape includes pharmaceutical manufacturers, healthcare technology companies, diagnostic suppliers, and specialized API providers. Competition is influenced by product quality, manufacturing capabilities, regulatory compliance, supply reliability, and formulation expertise.

Huaian Hualu Pharmaceutical, Aldaghton, Fujifilm Holdings, Trivitron Healthcare, Akorn, Lantheus Medical Imaging, Boehringer Ingelheim, Sigma Aldrich, GE Healthcare, Taj Pharma, Sonafi, and Lianchuan Pharmaceutical are among the companies profiled.

Market participants are expected to focus on improving production capabilities, strengthening distribution networks, and supporting applications in advanced diagnostic imaging. Companies capable of maintaining consistent API quality while addressing expanding clinical and research requirements can benefit from the projected growth toward USD 500 million by 2035.